3 Key Takeaways
Plain English Summary- 01Core Finding
Adapting the European Alliance of Associations for Rheumatology standardised operating procedures, an international multidisciplinary panel of 42 experts from 15 countries was assembled through the European Reference Network on Rare Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Diseases, and the Paediatric Rheumatology European Society.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
What This Means for You
These recommendations establish a comprehensive, evidence-graded framework for childhood CNS vasculitis. The absence of level 1 evidence across all domains points to the need for an international prospective registry and collaborative clinical trials.
The Discovery
Childhood central nervous system (CNS) vasculitis is a rare and serious disease for which no evidence-based consensus guidance, standardised terminology, or definitions of treatment response exist. We aimed to develop the first international recommendations for the diagnosis, classification, monitoring, and treatment of CNS vasculitis in children. Adapting the European Alliance of Associations for Rheumatology standardised operating procedures, an international multidisciplinary panel of 42 experts from 15 countries was assembled through the European Reference Network on Rare Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Diseases, and the Paediatric Rheumatology European Society. A systematic literature review across 4 databases identified 182 eligible studies, graded per the Oxford Centre for Evidence-Based Medicine hierarchy. A modified Delphi survey (42 respondents) was followed by a 2-day face-to-face consensus conference (26 voting members; ≥70% agreement required). The panel formulated 83 consensus statements (3 overarching principles, 14 principles, and 66 recommendations) across 7 clinical domains. Of 182 included articles, 152 (83.5%) reported paediatric data; no level 1 evidence was identified. Key advances include an 8-domain nomenclature system replacing the 'primary/secondary' dichotomy with 'idiopathic/disease-associated' terminology, a paediatric-specific vessel wall imaging interpretive principle, a prospective risk-stratification model for disease progression, genome-wide sequencing as the preferred genetic testing approach, and formal definitions of remission, relapse, and refractory disease. None of these elements had been previously codified for childhood CNS vasculitis.
How It Works, Simply
This immunology research focuses on immune response · Genetics. Researchers evaluated it using an observational cohort study at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Adapting the European Alliance of Associations for Rheumatology standardised operating procedures, an international multidisciplinary panel of 42 experts from 15 countries was assembled through the European Reference Network on Rare Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Diseases, and the Paediatric Rheumatology European Society.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study · Real-World Cohort
Biological Pathway & Modality
Immune response · Genetics
Intervention: ERN-RITA/PReS recommendations for the diagnosis, classification, monitoring, and
Experimental Findings & Endpoints
Childhood central nervous system (CNS) vasculitis is a rare and serious disease for which no evidence-based consensus guidance, standardised terminology, or definitions of treatment response exist.
We aimed to develop the first international recommendations for the diagnosis, classification, monitoring, and treatment of CNS vasculitis in children. Adapting the European Alliance of Associations for Rheumatology standardised operating procedures, an international multidisciplinary panel of 42 experts from 15 countries was assembled through the European Reference Network on Rare Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Diseases, and the Paediatric Rheumatology European Society.
A systematic literature review across 4 databases identified 182 eligible studies, graded per the Oxford Centre for Evidence-Based Medicine hierarchy. A modified Delphi survey (42 respondents) was followed by a 2-day face-to-face consensus conference (26 voting members; ≥70% agreement required).
The panel formulated 83 consensus statements (3 overarching principles, 14 principles, and 66 recommendations) across 7 clinical domains. Of 182 included articles, 152 (83.5%) reported paediatric data; no level 1 evidence was identified.
Key advances include an 8-domain nomenclature system replacing the 'primary/secondary' dichotomy with 'idiopathic/disease-associated' terminology, a paediatric-specific vessel wall imaging interpretive principle, a prospective risk-stratification model for disease progression, genome-wide sequencing as the preferred genetic testing approach, and formal definitions of remission, relapse, and refractory disease. None of these elements had been previously codified for childhood CNS vasculitis.
Clinical Translation & Practice Context
These recommendations establish a comprehensive, evidence-graded framework for childhood CNS vasculitis.
The absence of level 1 evidence across all domains points to the need for an international prospective registry and collaborative clinical trials.
The Bottom Line · Clinical Pearl
“These recommendations establish a comprehensive, evidence-graded framework for childhood CNS vasculitis.”
Published in Annals of the Rheumatic Diseases · Current Stage: Real-World Cohort
